Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Royalty Pharma plc RPRX

Healthcare Biotechnology
Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The Company collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio consists of royalties on over 35 commercial products, including... see more

Recent & Breaking News (NDAQ:RPRX)

Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Repros Therapeutics, Inc.

PR Newswire October 23, 2013

Repros Receives FDA Guidance For Androxal(R) Clinical Program

Globe Newswire October 22, 2013

Repros Announces Three Studies Accepted for Presentation at the Annual Meeting of the Sexual Medicine Society of North America

Globe Newswire October 7, 2013

Repros to Present at Biocentury's NewsMakers in the Biotech Industry Conference

Globe Newswire September 23, 2013

Repros Provides Additional Information Confirming Success for Study ZA-302

Globe Newswire September 18, 2013

Repros Reports Preliminary Findings: Second Pivotal Study and 6-Month Safety Study Support Androxal(R) Approvability

Globe Newswire September 16, 2013

Repros Reports 6 Month Bone Mineral Density Data From Ongoing Study ZA-303

Globe Newswire August 20, 2013

Repros Therapeutics Inc.(R) Reports Second Quarter 2013 Financial Results

Globe Newswire August 7, 2013

Repros Seeks to Affirm Its Intellectual Property Rights in Androxal(R)

Globe Newswire August 5, 2013

RDInvesting Provides Investors with Free In-Depth Equity Reports on DDD, RPRX, SSYS and SWHC

Accesswire July 30, 2013

Wall Street Fundamentals Releases New In-Depth Stock Reports on ANAC, RPRX, THLD and THRX

Accesswire July 17, 2013

Repros Announces Formation of Androxal(R) Clinical and Commercial Advisory Board

Globe Newswire July 9, 2013

Repros Therapeutics Inc.(R) Announces the Closing of Public Offering of Common Stock

Globe Newswire June 25, 2013

Wall Street Fundamentals Releases New In-Depth Stock Reports on BPAX, PPHM, RPRX and SGMO

Accesswire June 24, 2013

Repros Therapeutics Inc.(R) Announces Pricing of Public Offering of Common Stock

Globe Newswire June 19, 2013

Five Star Equities Issues New Research Reports on ACRE, FDS, RPRX and VRX

Accesswire June 19, 2013

Repros Therapeutics Inc.(R) Announces Proposed Public Offering of Common Stock

Globe Newswire June 17, 2013

Before the Bell Scans of BDX, MAKO, RPRX, and ALGN

Accesswire June 12, 2013

Repros to Webcast Investor and Analyst Day on June 6th

Globe Newswire June 3, 2013

FDA Recommends Running Phase 2b Trial of Proellex(R)-V in the Treatment of Severe Menstrual Bleeding Associated With Uterine Fibroids

Globe Newswire May 22, 2013